Dr Steve Ryder

Dr Steve Ryder

Consultant Physician in Hepatology and Gastroenterology

View full bio
Queens Medical Centre Campus, Derby Road, Nottingham, NG7 2UH
Publications
Title
Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primar
Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on
An analysis of rebleeding rates for variceal haemorrhage at a regional centre: what is the applicabi
Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary
In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and
Economic modelling of early transjugular intrahepatic portosystemic shunt insertion for acute varice
Response from Hepatitis C Trust, BASL, BIA, BVHG, BSG, and BHIVA to article asking whether widesprea
Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treat
Fast-food hyper-alimentation and exercise restriction in healthy subjects
Prediction of liver disease in patients whose liver function tests have been checked in primary care
Autoantibodies in chronic hepatitis C virus infection and their association with disease profile
Chronic hepatitis C - what do the new drugs offer and who should get them first?
Portal inflammation is associated with advanced histological changes in alcoholic and non-alcoholic
Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiv
Effectiveness of a nurse-led alcohol liaison service in a secondary care medical unit
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steat
The Road to a Successful Transjugular Intrahepatic Portosystemic Shunt (Tips) Service: Experience of
The hepatitis C revolution part 2: difficult-to-treat groups and experimental approaches. Current op
The hepatitis C revolution part 1: antiviral treatment options